←
JK Han MD15,268 posts
JK Han MD avatar

JK Han MD

@netta_doc

Cardiac Electrophysiologist• Professor• Board of Trustees HRS • #UCLA • #WomeninEP #EPeeps • #DigitalHealth •Tweets≠med advice 🏃🏻‍♀️🏕🏂☕️🐶🇹🇭

◷ Joined December 2010▧ 2,683 Photos and videos
JK Han MD avatar
JK Han MD@netta_doc·31 Mar 2025

✨PUBLISHED✨ Our scientific statement State of the Art of #ArtificialIntelligence in Clinical #Electrophysiology in 2025 We hope this new checklist helps both researchers & readers alike! Thank you @EmmaSvennberg & @DavidDuncker for the opportunity to contribute 🙏🏼 #EHRA2025

Post attachment

State of the art of #ArtificiaIIntelligence in clinical electrophysiology in 2025. A scientific statement of #EHRA_ESC, the Heart Rhythm Society (HRS), and the ESC Working Group in e-Cardiology academic.oup.com/europace/ad… @DavidDuncker @netta_doc #Europace

Post attachment
Jason Andrade avatar
⟳ JK Han MD retweeted
Jason Andrade@DrJasonAndrade·Oct 28

AF burden is increasingly being looked at as an outcome for clinical trials owing to the known limitations of time to event recurrence endpoints. In the attached clinical trials workshop we critically examine the role of AF burden as an outcome for clinical trials of AF interventions, evaluating the evidence supporting AF burden as well as providing framework for an analytic strategy. We also delve into complementary metrics such as LEAF (longest episode of AF) and AF density. @CardioUBC @DilawriCVI @VCHResearch evidence.nejm.org/doi/full/1…

Sanjiv Narayan avatar
⟳ JK Han MD retweeted
Sanjiv Narayan@S_NarayanMD·Oct 20

What's NEXT in cardiac electrophysiology and digital/Computational medicine? AI, digital twins, bioengineering, AF/VT ablation, and wearable technologies. Join us at Stanford Medicine, Oct 30, for EP in the West 2026—with leading innovators and rising investigators. REGISTER👇 In person (meet and greet, networking, lunch, cookies) + free online! stanford.cloud-cme.com/cours… @JoseJalife4 @AndreaSarkozy steve niederer @Dr_Santangeli @igorefimov @MehakDhande @TinaBaykaner @EldrinL @Wanginnovate @DrJackOSullivan @euanashley @StanfordHAI

Post attachment
Edward J Schloss MD avatar
⟳ JK Han MD retweeted
Edward J Schloss MD@EJSMD·Sep 30

Interesting piece. One question from the EP side: if interventional HF encompasses TEER, MCS, CCM, etc., shouldn’t CRT/CSP—one of the great success stories in HF—have a more central place? And if @HFSA @SCAI will co-own this emerging field, shouldn’t EP @HRSonline have a seat at the table?

Excellent statement on the journey so far and path forward toward interventional heart failure (IHF) as a discipline. Worth a read. Link: sciencedirect.com/science/ar… Title ⬇️

Post attachment
Mehak Dhande, MD (she/her) avatar
⟳ JK Han MD retweeted
Mehak Dhande, MD (she/her)@MehakDhande·Sep 19

Day one at #HRX2026 @experienceHRX is in the books! Looking forward to the next two days of this intentionally unconventional conference. Be there! #EPeeps

That's a wrap on Day 1 of HRX Live 2026! The Innovation Summit, our first Main Tent speaker, the opening pitch competition presentations — and we're just getting started. Stay tuned! More #HRX2026 coverage is coming your way, #EPeeps. @MehakDhande @OliverMonfredi @Nashwa_Salem_

5:06
Nassir Marrouche avatar
⟳ JK Han MD retweeted
Nassir Marrouche@nmarrouche·Sep 16

Very important message from our group. In patients with recurrent AF after a first ablation, what we do next matters. Repeat catheter ablation was associated with a 35% lower risk of death, stroke, or HF hospitalization compared with cardioversion, with an NNT of only 14. This challenges the idea that management of recurrent AF should simply be based on operator preference. Recurrence after ablation should not be viewed as failure—it may be an opportunity to intervene again and improve meaningful clinical outcomes. Congratulations to @mabou_khalil @HanFengGHD @QMarashly and the entire team. #AFib #Ablation #EPeeps @PrashSanders @shivkumarmd @gautamsand @S_NarayanMD @Phiso_de @drsuneet @drjohnm @drluissaenz @leftbundle @KennethEllenbo1 @DrBradleyKnight @DrRoderickTung @atulverma_md

AF recurs in up to 50% post-ablation, what's next is often just operator preference. Our study in Europace of 3,100+ patients: redo ablation cut death/stroke/HF by 35% vs. cardioversion (NNT=14). 🫀⚡ @nmarrouche @HanFengGHD @QMarashly 📄 doi.org/10.1093/europace/eua… #AFib #EPeeps

Nassir Marrouche avatar
⟳ JK Han MD retweeted
Nassir Marrouche@nmarrouche·Aug 31

Important PVI-SHAM-AF trial—but interpretation matters. This was not ablation vs “nothing.” The sham arm included deep sedation, an invasive cath-lab procedure, intensive follow-up and, importantly, cardioversion when patients were in AF—itself an effective rhythm-control intervention. Yet ablation still produced substantially better rhythm control (73% vs 52% freedom from AF). With QoL assessed at only 6 months, are we measuring the effect of ablation—or comparing two active rhythm-control strategies? I would be cautious concluding that ablation does not improve symptoms. The study may instead demonstrate how difficult it is to design a truly inert sham for AF. #AFib #CatheterAblation #RhythmControl #PVI #ESCCongress @PrashSanders @drjohnm @chris_sohns @peterkistler3 @DJ_Lakkireddy @DrRoderickTung @TinaBaykaner @DrJasonAndrade @SteffelJ @netta_doc @TulaneHeart

One of the #ESCCongress highlights: #HOTLINE #LBCT PVI-SHAM-AF 🫀262 patients (~1/2 women! 👏🏽)with symptomatic AF → ablation vs sham 🫀At 6 mo, AF-related QoL improved in BOTH groups, with no significant benefit from ablation (P=.36) 🫀But ablation improved freedom from AF: 73% vs 52%. Better rhythm control ≠ necessarily better QoL @RoWachter I love the sham trials! Lancet: doi.org/10.1016/S0140-6736(2…

Post attachmentPost attachmentPost attachmentPost attachment
C. Michael Gibson MD avatar
⟳ JK Han MD retweeted
C. Michael Gibson MD@CMichaelGibson·Aug 29

EPIDAURUS trial: In patients with AF and ACS, dual antithrombotic therapy with DOAC and intensified P2Y12-inhibition with prasugrel or ticagrelor for 1 month was associated with a higher bleeding risk without reducing ischemic events compared to triple antithrombotic therapy. Download slides here: clinicaltrialresults.org/wp-…

Post attachmentPost attachmentPost attachmentPost attachment